Fig. 4

HBsAg prevalence with time in children aged < 5 years under status quo + PAP scenario and scaling up current interventions + PAP scenario, respectively. PAP, peripartum antiviral prophylaxis
HBsAg prevalence with time in children aged < 5 years under status quo + PAP scenario and scaling up current interventions + PAP scenario, respectively. PAP, peripartum antiviral prophylaxis